GenScript received the award on COVID Management Initiative of the Year, Biotechnology industry in the Singapore Business Review (SBR) Management Excellence Award 2021. GenScript showed strong commitment and support to global COVID-19 management including production of genes, proteins and peptides for SARS-CoV-2 vaccine development around the world and launched first FDA EUA (Emergency Use Authorization) neutralization antibody test kit, cPass™ SARS-CoV-2 neutralization antibody detection kit.

GenScript went through an intensive selection process by the judges based on the initiative and effectiveness implemented from the company to navigate current headwinds due to the pandemic and the impact it brought to the clients and public. The launch of cPass™ SARS-CoV-2 neutralization antibody detection kit is the key differentiator as it is part of the key for COVID-19 management. cPass™ neutralization antibody test can estimate vaccine induced protection for a population.

“It’s a great honor to receive this award from SBR, this is a real testament on GenScript various efforts and solutions for combatting the pandemic, especially cPass™ that has provided strong scientific and emotional confidence for us to live with covid-19.” said Dr. Li Yanfeng, head of IVD business development in GenScript Asia Pacific.

With the recent emerging SARS-CoV-2 variant of concern (VoC), Omicron, GenScript also plays a part to adapt cPass™ to detect neutralization antibody to Omicron, providing Omicron RBD/S1/N protein & oligo for vaccine studies, customized cell line for test kits development and lastly, to complement cPass™, Pseudovirus assay for detecting neutralizing antibodies to Omicron as a gold standard alternative.

Source: GenScript via PR Newswire